Search research articles
Contact Us
Filters
Showing results (211-220 of 364) with videos related to
Page
of 37
Sort By:
Journal of Crohn'S & Colitis
|
September 24, 2011
Results of the 2nd part Scientific Workshop of the ECCO. II: Measures and markers of prediction to achieve, detect, and monitor intestinal healing in inflammatory bowel disease
Marco Daperno, Fabiana Castiglione, Lissy de Ridder, et al.
Journal of Crohn'S & Colitis
|
September 7, 2024
Differences in the Adverse Event Burden of Corticosteroid Use in Inflammatory Bowel Disease as Reported Between Adverse Event Reporting Systems and a Patient Questionnaire
Eman Al Sulais, Edouard Louis, Bernd Bokemeyer, et al.
Clinical Biochemistry
|
May 21, 2008
Proteomics for prediction and characterization of response to infliximab in Crohn's disease: a pilot study
Marie-Alice Meuwis, Marianne Fillet, Laurence Lutteri, et al.
The American Journal of Pathology
|
October 18, 2016
Lymphoid Aggregates Remodel Lymphatic Collecting Vessels that Serve Mesenteric Lymph Nodes in Crohn Disease
Gwendalyn J Randolph, Shashi Bala, Jean-François Rahier, et al.
Inflammatory Bowel Diseases
|
August 25, 2017
Patients with Crohn's Disease with High Body Mass Index Present More Frequent and Rapid Loss of Response to Infliximab
Loic Guerbau, Romain Gerard, Nicolas Duveau, et al.
Acta Gastro-Enterologica Belgica
|
March 7, 2003
The role of aminosalicylates in the treatment of ulcerative colitis
Gert Van Assche, Filip Baert, Marc De Reuck, et al.
Gastro Hep Advances
|
August 12, 2024
Shorter Crohn's Disease Duration Is Associated With Better Clinical and Endoscopic Outcomes With Risankizumab in Phase 3 Studies
Laurent Peyrin-Biroulet, Jean-Frederic Colombel, Edouard Louis, et al.
Crohn'S & Colitis 360
|
April 24, 2026
Efficacy and safety of ABBV-154 in patients with moderately to severely active Crohn's disease: a phase 2b, randomized, double-blind, placebo-controlled trial
Walter Reinisch, Laurent Peyrin-Biroulet, Geert D'Haens, et al.
Talanta
|
August 6, 2010
Comparison of three methods for fractionation and enrichment of low molecular weight proteins for SELDI-TOF-MS differential analysis
Muriel De Bock, Dominique de Seny, Marie-Alice Meuwis, et al.
Journal of Crohn'S & Colitis
|
December 3, 2010
The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Definitions and diagnosis
Gert Van Assche, Axel Dignass, Julian Panes, et al.
Page
of 37
Search research articles
Search
Showing results (211-220 of 364) with videos related to
Sort By:
Page
of 37
Journal of Crohn'S & Colitis
|
September 24, 2011
Results of the 2nd part Scientific Workshop of the ECCO. II: Measures and markers of prediction to achieve, detect, and monitor intestinal healing in inflammatory bowel disease
Marco Daperno, Fabiana Castiglione, Lissy de Ridder, et al.
Journal of Crohn'S & Colitis
|
September 7, 2024
Differences in the Adverse Event Burden of Corticosteroid Use in Inflammatory Bowel Disease as Reported Between Adverse Event Reporting Systems and a Patient Questionnaire
Eman Al Sulais, Edouard Louis, Bernd Bokemeyer, et al.
Clinical Biochemistry
|
May 21, 2008
Proteomics for prediction and characterization of response to infliximab in Crohn's disease: a pilot study
Marie-Alice Meuwis, Marianne Fillet, Laurence Lutteri, et al.
The American Journal of Pathology
|
October 18, 2016
Lymphoid Aggregates Remodel Lymphatic Collecting Vessels that Serve Mesenteric Lymph Nodes in Crohn Disease
Gwendalyn J Randolph, Shashi Bala, Jean-François Rahier, et al.
Inflammatory Bowel Diseases
|
August 25, 2017
Patients with Crohn's Disease with High Body Mass Index Present More Frequent and Rapid Loss of Response to Infliximab
Loic Guerbau, Romain Gerard, Nicolas Duveau, et al.
Acta Gastro-Enterologica Belgica
|
March 7, 2003
The role of aminosalicylates in the treatment of ulcerative colitis
Gert Van Assche, Filip Baert, Marc De Reuck, et al.
Gastro Hep Advances
|
August 12, 2024
Shorter Crohn's Disease Duration Is Associated With Better Clinical and Endoscopic Outcomes With Risankizumab in Phase 3 Studies
Laurent Peyrin-Biroulet, Jean-Frederic Colombel, Edouard Louis, et al.
Crohn'S & Colitis 360
|
April 24, 2026
Efficacy and safety of ABBV-154 in patients with moderately to severely active Crohn's disease: a phase 2b, randomized, double-blind, placebo-controlled trial
Walter Reinisch, Laurent Peyrin-Biroulet, Geert D'Haens, et al.
Talanta
|
August 6, 2010
Comparison of three methods for fractionation and enrichment of low molecular weight proteins for SELDI-TOF-MS differential analysis
Muriel De Bock, Dominique de Seny, Marie-Alice Meuwis, et al.
Journal of Crohn'S & Colitis
|
December 3, 2010
The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Definitions and diagnosis
Gert Van Assche, Axel Dignass, Julian Panes, et al.
Page
of 37